Replication-incompetent adenoviral vectors have been under investigation as a platform to
carry a variety of transgenes, and express them as a basis for vaccine development. A …

Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

The Ad26.COV2.S vaccine 1 , 2 – 3 has demonstrated clinical efficacy against symptomatic
COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing …

Background The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus
disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy …

Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26…

Durability of Response after Ad26.COV2.S Vaccination In this study, investigators measured
immune responses in 20 participants who had received either one or two doses of the Ad26.…

Background Respiratory syncytial virus (RSV) can cause serious lower respiratory tract disease
in older adults, but no licensed RSV vaccine currently exists. An adenovirus serotype 26 …

Importance Developing effective vaccines against Ebola virus is a global priority. Objective
To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26.ZEBOV…

Since its emergence in late 2019, the coronavirus disease 2019 (COVID‐19) pandemic has
caused substantial morbidity and mortality. Despite the availability of efficacious vaccines, …